STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(19)30041-x ◽

2019 ◽

Vol 4 (5) ◽

pp. 376-388 ◽

Cited By ~ 8

Author(s):

Stine Braendegaard Winther ◽

Gabor Liposits ◽

Halla Skuladottir ◽

Eva Hofsli ◽

Carl-Henrik Shah ◽

...

Keyword(s):

Colorectal Cancer ◽

Combination Chemotherapy ◽

Phase 2 ◽

Open Label ◽

Reduced Dose ◽

Phase 2 Trial ◽

Vulnerable Patients ◽

Open Label Phase ◽

Dose Combination

Dose-Adjusted EPOCH Regimen as First-Line Treatment for Non-Hodgkin's Lymphoma with Hemophagocytic Lymphohistiocytosis: A Single-Arm, Open-Label, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3304299 ◽

2018 ◽

Author(s):

Jin-Hua Liang ◽

Li Wang ◽

Hua-Yuan Zhu ◽

Jun Qian ◽

Hui Liao ◽

...

Keyword(s):

Hemophagocytic Lymphohistiocytosis ◽

Hodgkin's Lymphoma ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Non Hodgkin's Lymphoma ◽

Open Label Phase ◽

First Line Treatment

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(20)30362-3 ◽

2021 ◽

Cited By ~ 2

Author(s):

Cornedine J de Gooijer ◽

Vincent van der Noort ◽

Jos A Stigt ◽

Paul Baas ◽

Bonne Biesma ◽

...

Keyword(s):

Malignant Mesothelioma ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Line Chemotherapy

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70330-4 ◽

2014 ◽

Vol 15 (10) ◽

pp. 1065-1075 ◽

Cited By ~ 881

Author(s):

Volker Heinemann ◽

Ludwig Fischer von Weikersthal ◽

Thomas Decker ◽

Alexander Kiani ◽

Ursula Vehling-Kaiser ◽

...

Keyword(s):

Colorectal Cancer ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(10)70175-3 ◽

2010 ◽

Vol 11 (9) ◽

pp. 845-852 ◽

Cited By ~ 182

Author(s):

Gianluca Masi ◽

Fotios Loupakis ◽

Lisa Salvatore ◽

Lorenzo Fornaro ◽

Chiara Cremolini ◽

...

Keyword(s):

Colorectal Cancer ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

First Line Treatment

An Open‐Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX‐6 as First‐Line Therapy for Metastatic Colorectal Cancer

The Oncologist ◽

10.1634/theoncologist.2014-0028 ◽

2014 ◽

Vol 19 (4) ◽

pp. 350-351 ◽

Cited By ~ 37

Author(s):

Rocio Garcia‐Carbonero ◽

Fernando Rivera ◽

Joan Maurel ◽

Jean‐Pierre M. Ayoub ◽

Malcolm J. Moore ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

Open Label ◽

Safety And Efficacy ◽

First Line Therapy ◽

Line Therapy ◽

Eltrombopag and Cyclosporine as First-Line Therapy in Patients with Severe Acquired Aplastic Anemia: A Two-part, 5-year, Single-Arm, Multicenter, Open-label, Phase 2 Trial (SOAR)

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2017.07.242 ◽

2017 ◽

Vol 17 ◽

pp. S389-S390

Author(s):

Phillip Scheinberg ◽

Joan Maier ◽

Ozlem Ocak Arikan ◽

Carlo Finelli ◽

Junho Jang

Keyword(s):

Aplastic Anemia ◽

Phase 2 ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Phase 2 Trial ◽

Line Therapy ◽

Prophylactic efficacy of ninjin’yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2)

International Journal of Clinical Oncology ◽

10.1007/s10147-020-01648-3 ◽

2020 ◽

Vol 25 (6) ◽

pp. 1123-1129

Author(s):

Yoshiharu Motoo ◽

Yasuto Tomita ◽

Hideto Fujita

Keyword(s):

Colorectal Cancer ◽

Peripheral Neuropathy ◽

Adjuvant Chemotherapy ◽

Phase 2 ◽

Open Label ◽

Postoperative Adjuvant Chemotherapy ◽

Prophylactic Efficacy ◽

Phase 2 Trial ◽

Interim Safety Results from Steam: a Randomized Phase 2 Trial of Sequential and Concurrent Folfoxiri–Bevacizumab (Bev) Vs Folfox–Bev for the First-Line (1L) Treatment (Tx) of Patients (Pts) with Metastatic Colorectal Cancer (Mcrc)

Annals of Oncology ◽

10.1093/annonc/mdu333.24 ◽

2014 ◽

Vol 25 ◽

pp. iv177 ◽

Cited By ~ 1

Author(s):

H. Hurwitz ◽

B. Tan ◽

J. Reeves ◽

H. Xiong ◽

H. Lenz ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

Randomized Phase 2

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(19)30272-4 ◽

2019 ◽

Vol 20 (8) ◽

pp. 1070-1082 ◽

Cited By ~ 43

Author(s):

Tanios S Bekaii-Saab ◽

Fang-Shu Ou ◽

Daniel H Ahn ◽

Patrick M Boland ◽

Kristen K Ciombor ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Dose Optimisation ◽